ストックスクリーナーアプリを入手
6.63
1.63%
-0.11
前日終値:
$6.74
開ける：
$6.77
24時間の取引高:
1.10M
Relative Volume:
1.28
時価総額：
$436.62M
収益：
$301.79M
当期純損益:
$-43.42M
株価収益率:
-9.8881
EPS:
-0.6705
ネットキャッシュフロー:
$-44.87M
1週間 パフォーマンス:
+1.84%
1か月 パフォーマンス:
+0.91%
6か月 パフォーマンス:
-7.66%
1年 パフォーマンス:
-28.71%
1日の値動き範囲:
$6.53
$6.90
1週間の範囲:
$6.47
$7.00
52週間の値動き範囲:
$3.86
$10.20
Evolus Inc Stock (EOLS) Company Profile
Compare EOLS vs TAK, HLN, TEVA, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EOLS
Evolus Inc
|
6.63 | 436.62M | 301.79M | -43.42M | -44.87M | -0.6705 |
TAK
Takeda Pharmaceutical Co Adr
|
15.63 | 49.39B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
8.96 | 39.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.48 | 36.66B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
78.71 | 33.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
536.59 | 22.78B | 3.17B | 1.29B | 1.01B | 27.09 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-06 | ダウングレード | Needham | Buy → Hold |
| 2025-04-17 | 開始されました | BTIG Research | Buy |
| 2024-01-29 | アップグレード | Barclays | Equal Weight → Overweight |
| 2022-06-23 | 開始されました | Needham | Buy |
| 2022-05-12 | アップグレード | Barclays | Underweight → Equal Weight |
| 2022-01-20 | アップグレード | Truist | Hold → Buy |
| 2021-05-06 | アップグレード | Mizuho | Neutral → Buy |
| 2021-04-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-02-24 | ダウングレード | Truist | Buy → Hold |
| 2020-07-07 | ダウングレード | Mizuho | Buy → Neutral |
| 2020-02-06 | 再開されました | Mizuho | Buy |
| 2019-11-26 | 開始されました | SVB Leerink | Outperform |
| 2019-09-05 | 再開されました | Mizuho | Buy |
| 2019-06-28 | 開始されました | Wells Fargo | Market Perform |
| 2019-06-11 | 開始されました | Barclays | Underweight |
| 2019-03-20 | 開始されました | SunTrust | Buy |
| 2019-02-14 | 開始されました | H.C. Wainwright | Buy |
| 2019-01-29 | 開始されました | Stifel | Buy |
すべてを表示
Evolus Inc (EOLS) 最新ニュース
Evolus Inc (EOLS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Evolus Inc (EOLS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Evolus Inc (EOLS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Evolus Inc (EOLS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Evolus Inc (EOLS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Evolus Inc (EOLS) Institutional Confidence - TradingKey
Evolus Inc (EOLS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Evolus Inc (EOLS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
EOLS Reiterated by BTIG -- Price Target Maintained at $13.00 - GuruFocus
Evolus Inc (EOLS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
[EFFECT] Evolus, Inc. SEC Filing - Stock Titan
Understanding the Setup: (EOLS) and Scalable Risk - Stock Traders Daily
Evolus shareholders re-elect directors and approve executive compensation By Investing.com - Investing.com Nigeria
Evolus shareholders re-elect directors and approve executive compensation - Investing.com
Evolus (EOLS) shareholders approve directors, auditor and say-on-pay at 2026 meeting - Stock Titan
Evolus, Inc. (EOLS) reports Q1 loss, tops revenue estimates - MSN
Mizuho Securities Maintains Evolus(EOLS.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Evolus (NASDAQ: EOLS) registers $250M shelf; $195.5M unsold re‑registered - Stock Titan
EOLS: Virtual Meeting with Management Scheduled on June 11 - GuruFocus
AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society - GlobeNewswire Inc.
The Technical Signals Behind (EOLS) That Institutions Follow - Stock Traders Daily
Evolus (EOLS) Q2 2025 Earnings Call Transcript - AOL.com
Evolus Shareholder Notice - TMX Newsfile
Evolus Update - TMX Newsfile
Evolus Class Action Reminder - TMX Newsfile
Evolus Shareholder Alert - TMX Newsfile
Earnings call transcript: Evolus Inc Q1 2026 misses EPS forecast, stock rises - Investing.com Nigeria
Precision Trading with Evolus Inc. (EOLS) Risk Zones - Stock Traders Daily
Evolus Q1 2026 earnings preview - MSN
Evolus to Participate in The Jefferies Global Healthcare Conference - Business Wire
Evolus To Roll Out Estyme Injectable Hyaluronic Acid Fillers in Europe - The Dermatology Digest
TradingKey - TradingKey
Evolus Completes Key NUCEIVA Safety Study, Easing Risk for Aesthetic Toxin Investors - TipRanks
Evolus (EOLS) to Launch Estyme Injectable Collection in Europe - GuruFocus
Evolus to launch Estyme dermal filler line in Europe on May 16 - Investing.com UK
Evolus to Launch Estyme Dermal Fillers in Europe - Orange County Business Journal
Evolus to launch Estyme dermal filler line in Europe on May 16 By Investing.com - Investing.com South Africa
Evolus, Inc. Launches Estyme Injectable Hyaluronic Acid Gels Collection in Europe - marketscreener.com
Evolus launches Estyme in Europe with commercial debut targeted for May 16 - Traders Union
Evolus Announces Commercial Launch Of Estyme® Injectable Hyaluronic Acid Gels In Europe - TradingView
Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe - ChartMill
What is HC Wainwright's Estimate for Evolus Q2 Earnings? - MarketBeat
Evolus May 2026 slides: HA innovation, Jeuveau data support dual strategy - Investing.com Australia
Evolus May 2026 slides: HA innovation, Jeuveau data support dual strategy By Investing.com - Investing.com South Africa
Evolus | 4: Statement of changes in beneficial ownership of securities-Officer MOATAZEDI DAVID - Moomoo
How sustainable is Evolus (EOLS) profit margins? (Bullish Sentiment) 2026-05-08Support Level Bounce - The Legal Advocate
Evolus, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:EOLS) 2026-05-07 - Seeking Alpha
Evolus reiterates 2026 net revenue of $327M-$337M while targeting a low to mid-single-digit adjusted EBITDA margin - MSN
Evolus Inc (EOLS) 財務データ
収益
当期純利益
現金流量
EPS
11.23%
0.45%
大文字化:
|
ボリューム (24 時間):